A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up
Kazandjian, Dickran, Korde, Neha, Mailankody, Sham, Zhang, Yong, Hsu, Jennifer, Hill, Elizabeth, Morrison, Candis, Divakarla, Sneha, Kwok, Mary L., Manasanch, Elisabet E., Bhutani, Manisha, Tageja, Nishant, Galera, Pallavi, Dulau-Florea, Alina, Salem, Dalia, Gonzalez, Esther, Lindenberg, Liza, Maric, Irina, Calvo, Katherine R., Braylan, Raul C., Yuan, Constance, Wilson, Wyndham H., Choyke, Peter, Stetler-Stevenson, Maryalice, Steinberg, Seth M., Figg, William, Roschewski, Mark, Landgren, Ola
Published in Blood (29.11.2018)
Published in Blood (29.11.2018)
Get full text
Journal Article